Chief Financial Officer, Treasurer

Biren Amin, MBA

all leadership

Mr. Amin joins Immuneering after having built a strong track record for nearly two decades on Wall Street covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology, and rare diseases. Prior to Immuneering, Mr. Amin spent nearly 10 years at Jefferies as Managing Director of Biotechnology Research. Previously, he spent time at other equity research firms such as WJB Capital Group, FTN Equity Markets, Stanford Financial, and Prudential Equity Group. Mr. Amin started his career at Aventis Pharma where he was Senior Manager in their scientific competitive intelligence group with business development. He holds an M.B.A. from Stern School of Business at New York University, a M.S. in Pharmacy from Long Island University, and a B.S. in Pharmacy from University of the Sciences in Philadelphia.
General Counsel, Secretary

Michael Bookman, J.D.

all leadership

Mr. Bookman has served as our General Counsel and Secretary since July 2021. Prior to joining Immuneering, Mr. Bookman served as General Counsel and Secretary of Frequency Therapeutics from September 2019 to July 2021. In this role, he was a member of the Executive Leadership Team and established and led Frequency’s Legal Department as its first in-house attorney. Mr. Bookman also played a key role in Frequency’s initial public offering in October 2019. Prior to his time at Frequency, Michael was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies.
Scott Barrett, M.D.
Chief Medical Officer

Scott Barrett, M.D.

all leadership

Dr. Barrett is an accomplished medical oncologist and R&D expert with more than 30 years of clinical and research experience in leadership positions at major institutions in industry and academia. He has spent the last decade gaining broad expertise in the fields of target and drug discovery, most recently, as executive director/ lead of global medical affairs for targeted oncolytic therapies at Incyte Pharmaceuticals. Dr. Barrett is a trained physician-scientist, earning his bachelor’s degree at The Johns Hopkins University as a Beneficial-Hodson Scholarship recipient. He then earned his medical degree from the University of Miami School of Medicine and completed his internal medicine residency at the Mayo Clinic in Rochester, Minn. At Memorial Sloan-Kettering Cancer Center, Dr. Barrett completed his fellowship in medical oncology where he co-authored a Phase 2, proof-of-concept study, which pioneered the use of paclitaxel for advanced breast cancer treatment in the ambulatory setting. Prior to entering the biopharmaceutical industry, he practiced academic and community-based hematology/oncology for 15 years. Dr. Barrett is board-certified in both internal medicine and in medical oncology.
Brett Hall
Chief Scientific Officer

Brett Hall, Ph.D.

all leadership

Dr. Hall is a pharmaceutical and biotechnology veteran (Janssen/J&J; Medimmune/AZ, Molecular Response; Asellus Therapeutics) with extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences including multiple drug registrations. He was the translational lead for Sylvant® (siltuximab) and Imbruvica® (ibrutinib) throughout clinical development, and his translational medicine teams developed and executed translational strategies for both Darzalex® (daratumumab) and Imfinzi® (durvalumab). Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences and holds multiple patents for drug pharmacology and discovery. Prior to his experience in the life sciences industry, Dr. Hall served in the United States Air Force and worked as a Series 6 and 63 licensed investment banker. After completing his graduate and postdoctoral studies, Dr. Hall was a tenure-track assistant professor at Ohio State University where his laboratory focused on development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers.
Ben Zeskind, Ph.D., MBA
Co-Founder, President, Chief Executive Officer, Director

Ben Zeskind, Ph.D., MBA

all board leadership

Dr. Zeskind co-founded Immuneering in 2008 with the goal of leveraging high-throughput data to improve pharma R&D. He is an inventor on numerous patents assigned to both Immuneering's partners and the company itself. Dr. Zeskind has published extensively in high-impact peer-reviewed journals. He trained at the Massachusetts Institute of Technology, earning a Ph.D. in Bioengineering in 2006 and an S.B. in electrical engineering and computer science in 2003. He also earned an MBA at Harvard Business School in 2008, where he was recognized as a Baker Scholar, the highest award for distinction.
Director of Financial Planning & Analysis

Christian Alaia, CPA

all

Mr. Alaia is a dedicated finance partner who thrives in high growth and fast paced environments. He began his career with the audit team at Sax LLP, after which he joined global pharmaceutical leader, Sanofi, where he specialized in accounting and finance. Prior to joining Immuneering, he was an integral part of the finance team at Immunomedics, assisting in building out the finance process and helping the business through successful commercialization of their lead product, Trodelvy. He is a CPA and holds a BS in Accounting from the State University of New York at Albany.
Image Coming Soon
Senior Computational Biologist

Chris Armoskus, Ph.D.

all

Dr. Armoskus combines experience in the field of neurobiology with the techniques of computational biology and bioinformatics. He earned his Ph.D. in Biostatistics from the Keck School of Medicine at USC while doing research at the Zilkha Neurogenetic institute. His thesis demonstrated important transcriptional differences in schizophrenia and developed a novel algorithm for the analysis of differential expression in RNA-Seq data. He works on the analysis of neurodevelopmental and neurodegenerative conditions at the genomic, transcriptomic, and epigenetic levels.
Associate Director of Operations

Amy Axel

all

Ms Axel is a highly skilled scientist with experience in academia (Nationwide Children's Hospital, Ohio, USA) and the pharmaceutical industry (Janssen/J&J in Belgium and USA). She has expertise in solid and hematologic tumors focusing on physiologically relevant models for tumor microenvironment and complex cell‐based assays to evaluate molecules with varying mechanisms of action. Moving from directing hypothesis driven biomarker research projects, internally and externally, Ms Axel transitioned to an operational role at Janssen executing biomarker strategies in clinical trials in early development. She graduated from Ohio State University with a BSc. in Molecular Genetics.
John Brothers
Senior Director, Bioinformatics

John Brothers II, Ph.D.

all

Dr. Brothers is a Bioinformatician with expertise in NGS data analysis and specializes in transcriptomics. He brings industry experience with working in team-based collaborative environments with clinicians, experimentalists, and bioinformaticists. He graduated with a B.S. in Bioinformatics from the Rochester Institute of Technology and a Ph.D. in Bioinformatics from Boston University. His doctoral thesis focused on identifying splice variants and novel genes associated with chronic lung disease in order to better characterize the lung transcriptome from patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.
Yoonjeong Cha
Senior Director, Computational Biology

Yoonjeong Cha

all

Since joining Immuneering, Ms. Cha has developed an expertise in multi-omic integration and mutation prioritization in cancer data. She holds a B.S. in Computer Science and Molecular Biology from the Massachusetts Institute of Technology. Before graduating, she spent a year at the Bioinformatics Institute at Seoul National University working on a method to identify differentially expressed signaling pathways. She also spent a summer at the Robert Koch Institute in Berlin, Germany, analyzing genomic and proteomic data from viruses. She won first place in the 10th Annual Merck/BE-BMES Undergraduate Research Poster Session.
Renan Escalante-Chong
Director, Disease Cancelling Technology

Renan Escalante-Chong, Ph.D.

all

Dr. Escalante-Chong is passionate about integrating the massive amounts of data generated in modern biology to transform disease management and treatment. He did his Ph.D. at the Department of Systems Biology at Harvard Medical School where he used quantitative molecular genetics to dissect signaling pathways. He completed his postdoctoral training at the Department of Biological Engineering at the Massachusetts Institute of Technology where he worked with the interdisciplinary teams of neuroLINCS and answerALS to generate molecular signatures of the neurodegenerative diseases ALS and SMA.
Director, Clinical Operations

Elisabeth Madec Foley

all

Ms. Foley has over 18 years of experience in clinical trials, spanning both CRO and Biotech companies. She started as a Clinical Research Associate, grew into project management and has most recently been leading research programs and clinical operations departments. From her commitment to making a difference in the lives of patients, she has developed a depth of knowledge in, as well as a true passion for, early Phase 1 oncology trials. She brings a creative approach to management, including strong teamwork, risk mitigation, problem solving, PI engagement and quality data results. She graduated from Tulane University with a Bachelor of Science in Cell and Molecular Biology.
Kevin Fowler
Vice President, Translational Research

Kevin D. Fowler, Ph.D.

all

Dr. Fowler brings deep expertise in biology and computational biology to our team. He joined Immuneering after completing his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology. His doctoral research was focused on computational immunology and signal integration in immune cell biology, and he conducted research at Harvard Medical School.
Jason Funt
Vice President, Translational Genomics

Jason Funt, Ph.D.

all

Dr. Funt’s focus is in synthesizing actionable insight from complex, heterogeneous high-dimensional data. He earned his Ph.D. in Computational and Systems Biology from MIT’s Biology Department. His thesis research, at both the Massachusetts Institute of Technology and the Broad Institute, focused on mapping evolutionary pathways of drug resistance from genomic and transcriptomic profiling of the pathogen Candida albicans.
Senior Manager, Accounting and Operations

Paula George, CPA

all

Ms. George started her career at PwC in the Pharma/Life Sciences Assurance practice, where she provided audit services to clients, including guidance on financial reporting requirements and internal controls compliance. Prior to joining Immuneering, Ms. George led FinTech Accounting and Operations at Advent Intermodal Solutions, where she collaborated with the commercial organization to build the digital payments and accounting infrastructure essential to support fast growth and international expansion. Ms. George received her B.S. in Accounting from Rutgers University, New Brunswick, NJ and is a Certified Public Accountant in New Jersey.
Vice President, Clinical Operations

Anastasia Gutierrez, M.D.

all

Dr. Gutierrez is a highly motivated, results-driven clinical research leader with medical background and about 20 years of experience in clinical drug development. Her research experience involves variety of investigational products (small molecule, cellular therapies, devices) and therapeutic areas, with focus on early phase Oncology. She combines deep industry knowledge with a proven track record of clinical trials execution across multiple functions. Dr. Gutierrez gained her MD degree in Smolensk State Medical Academy (Russia), and entered the biopharmaceutical industry after completing her clinical residency in internal medicine and fellowship in cardiology. She spent over 10 years working at the clinical CROs, including Pharm-Olam International and Sarah Cannon Development Innovations. Most recently, Dr Gutierrez has been leading Clinical and Safety Operations at Bellicum Pharmaceuticals, Houston-based biotech company focusing on cellular therapies.
Mo Kagalwala
Senior Director, Neurosciences

Mo Kagalwala, Ph.D. MBA

all

Dr. Kagalwala straddles neuroscience R&D and business leadership experience to develop innovative therapeutics for aging neurodegenerative disorders. He has extensively published high impact research in peer-reviewed journals. Prior to joining Immuneering, he co-founded Siragen Pharmaceuticals, where he led the small molecule drug discovery program for Alzheimer’s disease, from target identification through proof of concept, and lead optimization. Dr. Kagalwala completed his Ph.D. in Biochemistry at SIU School of Medicine (dissertation on chromatin remodeling), and then post-doctoral training at MD Anderson Cancer Center (Glioblastoma / Medulloblastoma), and the Salk Institute (adult neurogenesis and neurodegeneration). In 2015, he also earned an MBA at Rady School of Management, UC San Diego, where he was awarded the prestigious Foster fellowship, and recognized as a Rady Innovation Fellow for business assistance to technology acceleration and commercialization programs.
Lead Machine Learning Scientist

Sunny Myungsun Kang, Ph.D.

all

Dr. Kang aims to build robust, interpretable, and fair algorithms to accelerate vaccine and drug discovery. She earned her Ph.D. studying computational vaccine design where she applied principles from Statistical Physics and leveraged stochastic simulation techniques to make HIV vaccines more potent. Before joining Immuneering, she worked as a senior data scientist at Wayfair, developing new algorithms and upgrading a major machine learning pipeline. She has been involved with various initiatives working towards promoting access to life-saving medicines, including United Nations Development Program and GAiA at Berkman Klein Center. Most recently, she contributed as a research scientist at PathCheck Foundation and developed deep learning based algorithm for COVID-19 contact tracing using Bluetooth signals.
Jason Kim
Associate Director, Biomedical Informatics

Jason Kim

all

Mr. Kim is passionate about utilizing technology to accelerate research and development in the field of biomedicine. Prior to obtaining his M.S. in Biomedical Informatics from the Sackler Institute of Graduate Biomedical Sciences at NYU School of Medicine, he spent over five years working as a software implementation consultant specializing in the life sciences industry, where he led projects to configure, deploy, and manage the enterprise software development life cycle. He also graduated with a B.S./M.S. in Biomedical Engineering from Northwestern University.
Peter King, Ph.D.
Vice President, Head of Discovery

Peter King, Ph.D.

all

Dr. King is a pharmaceutical professional with over 16 years of drug discovery and development experience (Janssen R&D/Johnson & Johnson; SmithKLine Beecham). With experience ranging from early drug discovery and preclinical/translational sciences. Dr King gained his B.Sc. from the University of Leicester, UK, in Biological Sciences in 1996, and his Ph.D. in Diabetes and Endocrinology in 2000, from the University of Liverpool, UK. After 2 years of postdoctoral training, Dr King joined Janssen Pharmaceuticals in 2002 at the Beerse site in Belgium, as a Scientist and Senior Scientist, in the Metabolic Disorders and Oncology Teams. He led the preclinical oncology in vivo team, where he contributed to numerous NME declarations and IND filings. As part of the Oncology Biomarkers Team, he was responsible for the Ex Vivo Center of Excellence for humanized model development. In 2012, Dr King joined the Molecular Imaging Team at the Janssen Spring House site in USA and lead the imaging program to support the Oncology Therapeutic Area.
Sarah Kolitz, Ph.D.
Vice President, Translational Medicine

Sarah Kolitz, Ph.D.

all

Dr. Kolitz brings expertise in teasing apart biological mechanisms to our team. She conducted her postdoctoral research in Biological Engineering at the Massachusetts Institute of Technology, after earning a Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine.
Rajaraman Krishnan, Ph.D.
Senior Director, Neurosciences

Rajaraman Krishnan, Ph.D.

all

Dr. Krishnan brings expertise in understanding cellular responses to protein misfolding events and developing therapies to mitigate toxicity associated with these conditions. Over the last decade he was involved in designing Ig-fusion-based therapeutics to treat Alzheimer’s disease and Systemic Amyloidosis. Prior to joining the biotech industry, he conducted his postdoctoral research at the Whitehead Institute of Biomedical Research (MIT) and earned a PhD in Biophysics and Molecular Biology from the Center for Cellular and Molecular Biology, Hyderabad, India.
Rebecca Kusko
Vice President, Business Development & Corporate Affairs

Rebecca Kusko, Ph.D.

all

Dr. Kusko is a computational biologist with expertise in translating NGS and other genomic data to clinical discoveries and actionable insights. In five years at Immuneering, Dr. Kusko has published 14 journal articles and three textbook chapters spanning best practices, neurodegeneration, oncology, computational toxicology, drug mechanism of action and biomarker development. She is a founding member and current deputy board chairperson of the FDA-led Massive Analysis and Quality Control (MAQC) Society. Dr. Kusko has integrated directly with clinicians on study design, as well as with lab scientists in functional genomics, to plan molecular biology and validation experiments. After completing her undergraduate degree in biological engineering at the Massachusetts Institute of Technology (MIT), she went on to complete her Ph.D. in computational biomedicine at the Boston University School of Medicine where her doctoral thesis focused on the transcriptome in chronic obstructive pulmonary disease (COPD) and lung cancer in never-smokers. Dr. Kusko is a guest lecturer at MIT and Boston University.
Andrew Lysaght
Vice President, Head of Bioinformatics

Andrew Lysaght, Ph.D.

all

Dr. Lysaght integrates years of experience with biological expression data together with a rigorous background in engineering fundamentals to provide expertise in customized data analysis with an eye for practical and actionable results. He earned a Ph.D. from the joint Harvard-MIT Program in Health Sciences and Technology, where he worked alongside leading clinicians of the Massachusetts Eye and Ear Infirmary to identify changes in inner ear transcription and translation during delayed onset hearing loss.
Melissa Martin
Executive Administrative Assistant

Melissa Martin

all

Ms. Martin has several years of experience in office administration in various industries, as well as a broad background in customer relations, social media and marketing, human resources and recruiting, and finance. She holds a B.S. in Communications from Fitchburg State University.
Vice President, Finance

Mallory Morales, CPA

all

Ms. Morales is a forward-thinking finance executive and CPA with 15+ years of achievements. Focused on accuracy, integrity and bottom-line orientation in high growth environments including start-ups and multi-billion dollar organizations with deep pharmaceutical and biotechnology finance experience. She began her career with PwC in the Assurance Practice supporting various industries. Prior to joining Immuneering Ms. Morales was the Director and Assistant Controller of FP&A at Immunomedics, serving as a thought leader and business partner to the executive team. She was instrumental in building out FP&A process and preparing the Company for commercialization and eventual sale to Gilead Sciences. She is a Certified Public Accountant and has a BS in Accounting and Business Administration from The State University of New York at Albany.
Computational Biologist

Ajay Obla, Ph.D.

all

Dr. Obla is a computational biologist with diverse experience in the field of genomics. He received his PhD in Molecular Cell Biology from University of Connecticut. His doctoral work involved the study of ribosomal protein gene family evolution in mammals and development of a novel classifier for single cell RNA seq library QC. He then worked as a bioinformatician for four years at the Mount Sinai Hospital (MSH) in NYC, contributing primarily to their pathogen surveillance initiative. Dr. Obla’s work at MSH involved assembling high quality genomes of various bacterial & viral pathogens followed by integration with electronic medical record data to perform genomic epidemiology. Dr. Obla was also involved in various multi-omic clinical research studies at MSH.
Computational Biologist

Aparna Rajpurkar, Ph.D.

all

Dr. Rajpurkar is a computational biologist with extensive experience in genomics, machine learning, and the biology of gene regulation. Her prior work includes integration of immune single cell expression datasets, algorithm development in genomics and image processing, and applying machine learning to biological problems. She earned her PhD from Stanford University School of Medicine in Genetics. Her thesis work focused on developing deep learning-based methods to understand the relationship between chromatin folding and gene regulation.
Computational Biologist

Ian Rose, Ph.D.

all

Dr. Rose is a computational biologist with experience integrating large single cell and bulk genomic datasets to address problems relating to public health, stem cells, and cancer biology. He received his Ph.D. from Cornell University’s Genetics, Genomics and Development program. His thesis work focused on understanding the molecular mechanisms underlying malignant transformation in the Fallopian tube.
J.L. Ross, Ph.D.
Vice President, Head of Neuroscience

J.L. Ross, Ph.D.

all

For over a decade, Dr. Ross studied at the National Institutes of Health, where he designed and conducted original research in the field of bioinformatics and comparative genomics. His work has been recognized for enhancing computational methods to identify and analyze molecular mechanisms that regulate neurogenesis. Dr. Ross has developed and employed machine learning and bioinformatic algorithms to decode the combinatorial logic of noncoding DNA that control gene expression programs. He earned his Ph.D. degree in Neuroscience from Brown University.
Image Coming Soon
Computational Biologist

Farrah Roy, Ph.D.

all

Dr. Farrah Roy (they/them) is a wet-lab molecular biologist turned bioinformatician with several years worth of experience analyzing NGS data and bioinformatics. They earned a B.A. in Biology at Wheaton College, MA. Their Ph.D thesis work - completed at Tufts Graduate School of Biomedical Sciences - focused on understanding the regulation and expression patterns of endogenous retroviruses in cancer, relying on a mixture of wet-lab and dry-lab technologies. Upon obtaining their Ph.D in Genetics, they moved on to a postdoctoral fellowship position at the Harvard T.H. Chan School of Public health, where they developed an RNA-sequencing pipeline used to identify endogenous and exogenous viral reads within a given data set. They have participated in a number of conferences to present their work, authored several manuscripts, and have collaborated on several projects involving NGS data and viral detection.
Senior Director, Corporate Controller

Stephen Sebastian, CPA

all

Mr. Sebastian brings over 13 years of extensive technical accounting, financial reporting and internal controls expertise. Prior to joining Immuneering, Mr. Sebastian was a Director at PwC in the SEC Services Group of the National Quality Office where he advised clients on their SEC reporting. He started his career at PwC in the Pharma/Life Sciences Assurance practice where he provided audit services to his clients, which included advising them on technical accounting topics in addition to financial reporting requirements and internal controls. Stephen received his B.S. in Accounting from King’s College, Wilkes Barre, Pennsylvania and is a Certified Public Accountant in New Jersey.
Rajeev Shrimali, Ph.D.
Director, Discovery Oncology Therapeutics

Rajeev Shrimali, Ph.D.

all

Dr. Shrimali is an accomplished immunologist and immune therapist bringing over 15 years of expertise in the field of Immuno-Oncology (IO). His research interest and expertise include tumor microenvironment (TME) and immune regulation, immune check point inhibitors / co-stimulators, development of biologics and targeted cancer immune therapies and identification of clinical biomarkers. His major endeavor involves development of corrective combinational cancer therapies and delineating their cellular and molecular immune potentiating mechanism of action. His published research highlights the significance of timing and sequence of targeting various immune checkpoints and the immune context of the TME, that can determine the therapeutic outcome. He received his Ph.D. in biochemistry from Indian council of medical research, Mumbai university, India. During his postdoctoral training, he had the privilege to work with Dr. Steven A. Rosenberg at NCI / NIH, the pioneer in the field of cancer immunotherapy. Following that, he has held various scientific and leadership positions as senior scientist, group leader and Director IO at some of the most esteemed organizations including Aurigene Discovery Technologies Ltd., Peloton Therapeutics and MD Anderson Cancer Center. In above positions, he has been the immunology lead of various oncology and inflammation programs right from early target discovery through IND filing and further out licensing or patient trials of clinical candidate.

Outside work he enjoys spending time in traveling with his family, Indian cooking, stage / theater acting and hosting live radio shows.

Image Coming Soon
Vice President, Clinical Development Scientist

Chris Walker

all

Mr. Walker comes to Immuneering with 25 years of experience in pharmaceutical research across multiple phases of clinical drug development, having held positions of increasing responsibility in site monitoring and trial management on the CRO and sponsor sides, alike. Immediately prior to Immuneering, Chris served as a Director of Clinical Development (Clinical Scientist) at Incyte Corporation where he was responsible for the authoring, execution, and evaluation of multiple early-phase and registration-track oncology and hematology trials. He earned his Bachelor of Science degree in Biology from Syracuse University.
Computational Biologist

Frank Wang, Ph.D.

all

Dr. Wang has been working on integrating computational approaches and biological data to investigate the biology underlying human diseases for over 8 years. He earned his Ph.D. in Bioinformatics from Department of Information and Communication Engineering, Huazhong University of Science and Technology, China. During his Ph.D. career, he spent two years in Genetics at Dartmouth College as a visiting scholar. His major research focus was computationally identifying novel biomarkers for predicting survival outcomes in breast cancer. During his postdoctoral research in the Department of Biomedical Data Science at Geisel School of Medicine at Dartmouth he worked on drug repositioning, novel biomarkers identification, and patients ‘intrinsic’ subsets classification in Systemic Sclerosis (SSc, a rare autoimmune disease) in the Whitfield lab. Frank then became a research scientist in the same lab and continued his computational research in SSc. He has interest and expertise in performing computational analyses in different biological data types including microarray, DNA methylation, ChIP-seq, single-cell/bulk RNA-seq, and ATAC-seq data.
Jenny Zhang, Ph.D.
Director, Genomic Data Science

Jenny Zhang, Ph.D.

all

Dr. Zhang extracts actionable insights from genomic data by combining cutting-edge data science techniques with expertise in experiment design and cancer biology. During her data science fellowship at The Data Incubator, she utilized distributed computing, network analysis, and machine learning to reveal patterns within large textual and numerical datasets. She graduated from the Massachusetts Institute of Technology with a B.S. in Physics, and Duke University with a Ph.D. in Genetics and Genomics. In her doctoral work, she developed novel experimental and bioinformatic methods to generate and analyze terabytes of next-generation sequencing data towards understanding the mutational underpinnings of lymphoma.
Board Member

Ann Berman

all board

Ann E Berman has more than fifteen years of board service in diverse industries. She currently serves as a member of the board of directors of Loews Corporation and a member of the board of trustees of Beth Israel Deaconess Medical Center and is the Chairwoman of its Compliance and Risk Committee. From September 2011 until June 2021, Ms. Berman served as a member of the board of directors and Chair of the Audit Committee of Cantel Medical Corp. She served as a member of the board of directors and Chair of the Audit Committee of Eaton Vance Corporation from February 2006 until March 2021. Prior to these roles, Ms. Berman served in various financial and risk management capacities at Harvard University, including as Senior Advisor to the President of Harvard University and Vice President of Finance and Chief Financial Officer. She received her B.A. with distinction in French language and literature from Cornell University, where she was Phi Beta Kappa, and her M.B.A. from the University of Pennsylvania’s Wharton School of Business. She is a Certified Public Accountant.
Bob Carpenter
Co-founder, Chairman of the Board

Bob Carpenter, M.S., MBA

all board

Mr. Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He served on Genzyme’s board of directors from 1994-2011 and was executive vice president of Genzyme from 1989-1991 as well as chairman of its subsidiary IG Laboratories. He founded and served in executive management and board roles at numerous biotech companies, including Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme, and VacTex, which was acquired by Aquila Biopharmaceuticals. Mr. Carpenter is currently chairman of Hydra Biosciences. Mr. Carpenter is a graduate of West Point. He earned his master’s degree in computer science from Stanford University and his MBA from Harvard Business School.
Peter Feinburg
Board Member

Peter Feinberg

all board

Mr. Feinberg has more than three decades of experience in the financial services industry at Oppenheimer & Co. He is a founding member of Boxcar Partners, a venture capital investment firm comprised of several family offices with a focus area in biotech investing. He is a founder of multiple companies including BridgeBio, which invests in preclinical, non-public, rare genetic disease assets, North Coast Partners, a real estate holding company that invests in Detroit. He is an advisory board member of Ignite Power, an African solar energy company, currently the largest in Rwanda, which has created a life changing experience for its citizens and Sporos Bioventures. Mr. Feinberg earned his bachelor’s degree in finance from Whittier College.
Board Member

Laurie Keating, J.D.

all board

Laurie Bartlett Keating is Executive Vice President and Chief Legal Officer of Alnylam Pharmaceuticals (ALNY), the leading RNAi company with 4 RNAi therapeutics approved and launched in less than three years beginning in 2018. She has more than 25 years of executive experience at biotechnology and high-tech companies. Prior to joining Alnylam in 2014, Laurie served as Senior Vice President and General Counsel of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high-growth technology companies, including Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team.
She has a Doctor of Jurisprudence degree from the University of California, Hastings College of the Law, graduating Order of the Coif, and a BA in Economics from the University of California at Berkeley where she was elected to the Prytanean Honor Society. Laurie is a member of the Board of Directors of Immuneering Corporation and MassBio, and a past chair of the BIO General Counsels Committee.
Joseph Keskt
Observer, Board of Directors

Joseph Kekst

all board

Mr. Kekst is a founding member of Boxcar Partners, a venture capital investment firm comprised of several family offices with a focus area in biotech investing. He serves on the board of advisors at The Jewish Theological Seminary and is a board member at the Weizmann Institute of Science. He is also a founder of Sporos Bioventures. Mr. Kekst earned his bachelor’s degree from Brandeis University.
Board Member

Andy Phillips, Ph. D.

all board

Andy Phillips, Ph. D. is a Managing Director at Cormorant Asset Management, LP (“Cormorant”). Before joining Cormorant, Andy was the President and Chief Executive Officer of C4 Therapeutics, a company pioneering targeted protein degradation medicines. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at the Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University and a Full Professor of Chemistry and Biochemistry at the University of Colorado.

Andy holds Ph.D. and B.Sc. Hons. degrees in Biochemistry and Chemistry from the University of Canterbury (Christchurch, New Zealand). His academic research and accomplishments have been recognized by a number of national and international awards including the ACS Cope Scholar Award.

Computational Biology Advisory Board
Co-chair, Scientific Advisory Board

Max Artyomov, Ph. D.

advisory

Dr. Artyomov is an assistant professor of immunology and pathology at Washington University in St. Louis. His research is focused on developing an integrated experimental and computational pipeline to address important biological problems by leveraging the power of next-generation sequencing. His approach combines the power of systems immunology with high-throughput sequencing, mathematical modeling and statistical physics. Dr. Artyomov earned a Ph.D. in chemistry at the Massachusetts Institute of Technology (MIT) with a focus on computational immunology before conducting his postdoctoral research at the Broad Institute of Harvard and MIT.
Co-chair, Scientific Advisory Board

Doug Lauffenburger, Ph.D.

advisory

Dr. Lauffenburger is the former head of the department of biological engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology and applied mathematics. He has filed numerous patents, authored a key textbook on receptor-ligand binding and trafficking dynamics and published more than 200 peer-reviewed articles.
Oncology Advisory Board
Scientific Advisory Board

Daniel Ahn, M.D.

advisory

Dr. Ahn is an assistant professor at the Mayo Clinic and is the director of the GI Oncology Translational Research Working Group. He is a member on the Academic and Community Cancer Research United (ACCRU) Board of Directors. Dr. Ahn is an experienced clinical study program leader and is well-positioned to provide clinical insights into the predicted therapeutic index (efficacy vs safety) across early-stage compounds in this treatment space. His peer reviewed publications focus around early therapeutic clinical trials in GI-Oncology and he is well-recognized as a sub-specialist in hepatobiliary malignancies.
Scientific Advisory Board

Tanios Bekaii-Saab, M.D.

advisory

Dr. Bekaii-Saab is a professor of medicine at the Mayo Clinic and leads the Mayo Clinic-supported cancer research consortium Academic and Community Cancer Research United (ACCRU). He is a leading clinician-scientist in the Alliance for Clinical Trials in Oncology, a National Cancer Institute (NCI)-supported cooperative research group. Dr. Bekaii-Saab was a key author on two clinical manuscripts describing the muscle preservation benefits of MEK inhibition for cancer cachexia. Dr. Bekaii-Saab provides a clinician’s perspective on MEK inhibitors for cancer cachexia.
Scientific Advisory Board

Mitesh J. Borad, M.D.

advisory

Dr. Borad is the director of the Cancer Cell, Gene, and Virus (CGV) Therapy lab at the Mayo Clinic Center for Individualized Medicine (CMI). He is a top-tier researcher, educator and clinician having served as director of the CGV Lab and director of the Liver & Biliary Cancer Research Program at the Mayo Clinic. He has also held the position of vice-chair of the International Cholangiocarcinoma Research Network (ICRN) of the Cholangiocarcinoma Foundation. Dr. Borad is the co-chair of the Mayo Clinic Hepatobiliary Cancers CME-accredited International Review Symposium.
Scientific Advisory Board

Denis C. Guttridge, Ph.D.

advisory

Dr. Guttridge is the director of the Charles P. Darby Children’s Research Institute and associate director of translational sciences for Hollings Cancer Center at the Medical University of South Carolina (MUSC). Dr. Guttridge's research focuses on the cancer syndrome cachexia which contributes to poor prognosis and a reduced quality of life. He has also led cancer cachexia and pancreatic cancer programs. His other research interests include pancreatic cancer and childhood illnesses related to skeletal muscle defects including Duchenne muscular dystrophy and a childhood cancer called rhabdomyosarcoma. Dr. Guttridge is the senior author on a key publication showing the effectiveness of MEK inhibitors in a cancer cachexia mouse model and brings his expertise in cancer cachexia molecular biology, muscle biology and in vivo models.
Scientific Advisory Board

Bijan Nejadnik, M.D.

advisory

Dr. Nejadnik is chief medical officer and head of research at SanBio, Inc. Dr. Nejadnik has more than two decades of experience in large pharma and small biotech companies. He has led research teams in academic institutions and programs from early phase to registration trials, with successful BLA/NDA/MAA submissions and market launch. He was teaching faculty at University of California and Stanford University. He held multiple key roles at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in Alzheimer diseases immunology, autoimmune disorders, hematology and oncology. He previously served as executive director at Jazz Pharmaceuticals where he led the clinical team towards an approved biologic license application (BLA) and was the lead of medical affairs division, overseeing the launch of newly approved agents in their portfolio. Dr. Nejadnik earned his undergraduate degree and M.D. from the University of Louvain in Belgium.